COVID-19 IMMUNITY TASK FORCE

Spotlight on CITF-FUNDED RESEARCH

CITF Events

COVID-19 IMMUNITY TASK FORCE | GROUPE DE TRAVAIL SUR L'IMMUNITÉ FACE À LA COVID-19 | CanCOVID

Seminar Series | Research Results & Implications

How long does immunity to COVID-19 last?

Waning immunity, boosters, and dosing intervals

January 24, 2022 | 12:30 p.m. to 2:00 p.m. EST

REGISTER NOW TO ATTEND!

With the arrival of Omicron and the looming threat of other emerging variants, the crucial question on everyone's mind is: how long does immunity to SARS-CoV-2 last? The evidence will be essential to determining Canada's booster strategy that aims to mitigate future waves of infection, prevent undue stress on the healthcare system, and keep the population safe.

Register to attend our next *Research Results & Implications* seminar, during

which CITF experts will explain the reasons behind waning antibody levels, the importance of other features of the immune system, the effects of Omicron on immunity and vaccine effectiveness, the need for vaccine boosters, and the best dosing intervals to achieve maximum protection.

Our expert participants include **Dr. Tim Evans**, Executive Director of the CITF, **Dr. Jeff Kwong** of ICES, Public Health Ontario and the University of Toronto, **Dr. Dawn Bowdish** and **Dr. Andrew Costa** of McMaster University, and **Dr. Victor Ferreira**, on behalf of **Dr. Deepali Kumar**'s lab at the University Health Network, Toronto. The discussion will be moderated by **Dr. Nazeem Muhajarine** from the University of Saskatchewan and member of CoVaRR-Net.

REGISTER HERE

CITF-Funded Research Results

Booster doses stimulate strong antibody responses, including in older adults

While two doses of COVID-19 vaccine can prevent serious illness in most cases, vaccine-induced immune responses decline naturally over time, which leads to an increased risk of breakthrough infections. A pre-print, not-yet peer-reviewed, from CITF-funded researchers Dr. Mark Brockman of Simon Fraser University, Dr. Zabrina Brumme of Simon Fraser University and the BC Centre for Excellence in HIV/AIDS, and Dr. Marc Romney, from Providence Health Care and the University of British Columbia, showed that a third (booster) dose of vaccine elevated both the levels of antibodies and their neutralizing capacity above that of two doses in all individuals, including older adults.

Read More

CITF Modelling

Natural antibody wane reinforces importance of vaccination

In this month's analysis, the CITF modelled the effect of waning antibodies, known as seroreversion, to account for the natural loss of antibodies that occurs through time. These calculations, based on the most recent research on time to antibody wane, found that as of November 30, 2021, an estimated 1 in 21 Canadians (4.7%) still had detectable antibodies due to a previous infection. The data were prior to widespread exposure to the Omicron variant. Notably, this estimate is lower than our previous month's estimate of seroprevalence (7.8%), which did not incorporate seroreversion rates.

Read More

CITF Announcement



Available Now: the January edition of the CITF Monthly Review

This month's issue features:

- Expert commentary on how immunity to COVID-19 wanes over time, making booster vaccines essential;
- The latest CITF modeling & Canadian Blood Services data on immunity across Canada;
- SARS-CoV-2 in schools
- Vaccine safety
- More!

Read the complete magazine here

Share!

Know policymakers or researchers who may be interested in our latest research results? Please share this email and encourage them to subscribe!

Sign Up

Have a publication we should review or know about? Please share with us at **research@covid19immunitytaskforce.ca**

Missed an issue of Research Roundup? **View back issues.**
